August 11, 2026
Global Health Leaders Convene: Honoring Excellence, Addressing Conflict, and Rethinking Chronic Care global-health-leaders-convene-honoring-excellence-addressing-conflict-and-rethinking-chronic-care

Global Health Leaders Convene: Honoring Excellence, Addressing Conflict, and Rethinking Chronic Care

Basiran June 22, 2026
GENEVA – The 79th World Health Assembly (WHA) reached a pivotal midpoint this week, as international delegates...
Read More Read more about Global Health Leaders Convene: Honoring Excellence, Addressing Conflict, and Rethinking Chronic Care
FDA Approves Datopotamab Deruxtecan (Datroway) as Transformative First-Line Therapy for Triple-Negative Breast Cancer fda-approves-datopotamab-deruxtecan-datroway-as-transformative-first-line-therapy-for-triple-negative-breast-cancer

FDA Approves Datopotamab Deruxtecan (Datroway) as Transformative First-Line Therapy for Triple-Negative Breast Cancer

Jia Lissa June 22, 2026
WASHINGTON D.C. — In a move that marks a significant paradigm shift in the treatment of one...
Read More Read more about FDA Approves Datopotamab Deruxtecan (Datroway) as Transformative First-Line Therapy for Triple-Negative Breast Cancer
Global Health at a Crossroads: World Health Assembly Addresses Critical Challenges in Disease Control and Information Integrity global-health-at-a-crossroads-world-health-assembly-addresses-critical-challenges-in-disease-control-and-information-integrity

Global Health at a Crossroads: World Health Assembly Addresses Critical Challenges in Disease Control and Information Integrity

Neng Nana June 22, 2026
The recent sessions of the World Health Assembly (WHA) have marked a pivotal moment in international health...
Read More Read more about Global Health at a Crossroads: World Health Assembly Addresses Critical Challenges in Disease Control and Information Integrity
Landmark Study: Personalized mRNA Cancer Vaccine Sustains 49% Reduction in Melanoma Recurrence After Five Years landmark-study-personalized-mrna-cancer-vaccine-sustains-49-reduction-in-melanoma-recurrence-after-five-years

Landmark Study: Personalized mRNA Cancer Vaccine Sustains 49% Reduction in Melanoma Recurrence After Five Years

Suro Senen June 22, 2026
In a significant breakthrough for oncology, a long-term study has revealed that a personalized mRNA vaccine, when...
Read More Read more about Landmark Study: Personalized mRNA Cancer Vaccine Sustains 49% Reduction in Melanoma Recurrence After Five Years

You may have missed

vaderis-therapeutics-secures-152-million-in-series-b-funding-to-advance-breakthrough-hht-treatment

Vaderis Therapeutics Secures $152 Million in Series B Funding to Advance Breakthrough HHT Treatment

Asro August 11, 2026
the-great-shift-understanding-the-2025-medicaid-work-requirement-mandate

The Great Shift: Understanding the 2025 Medicaid Work Requirement Mandate

Nila Kartika Wati August 11, 2026
the-gentle-path-why-passive-yoga-is-the-secret-to-unlocking-tight-hips

The Gentle Path: Why Passive Yoga is the Secret to Unlocking Tight Hips

Iffa Jayyana August 11, 2026
unraveling-the-nf-1-enigma-beyond-genes-a-new-frontier-in-understanding-tumor-growth

Unraveling the NF-1 Enigma: Beyond Genes, A New Frontier in Understanding Tumor Growth

Nana August 11, 2026